Future directions for meningitis surveillance and vaccine evaluation in the meningitis belt of sub-Saharan Africa
RT Novak, O Ronveaux, AF Bita, HF Aké… - The Journal of …, 2019 - academic.oup.com
Abstract In sub-Saharan Africa, bacterial meningitis remains a significant public health
problem, especially in the countries of the meningitis belt, where Neisseria meningitidis …
problem, especially in the countries of the meningitis belt, where Neisseria meningitidis …
MenAfriNet: a network supporting case-based meningitis surveillance and vaccine evaluation in the meningitis belt of Africa
JC Patel, HM Soeters, AO Diallo… - The Journal of …, 2019 - academic.oup.com
Meningococcal meningitis remains a significant public health threat, especially in the African
meningitis belt where Neisseria meningitidis serogroup A historically caused large-scale …
meningitis belt where Neisseria meningitidis serogroup A historically caused large-scale …
[HTML][HTML] Less than one-fifth of Ethiopian children were vaccinated for measles second dose; evidence from the Ethiopian mini demographic and health survey 2019
AG Muluneh, MW Merid, B Tigabu, MG Ferede… - Vaccine: X, 2022 - Elsevier
Ethiopia introduced the measles second dose vaccine from the routine expanded
immunization program in 2018. Shreds of evidence are scarce on the measles second dose …
immunization program in 2018. Shreds of evidence are scarce on the measles second dose …
[HTML][HTML] Assessment of missed opportunities for vaccination (MOV) in Burkina Faso using the World Health Organization's revised MOV strategy: Findings and …
L Kaboré, B Meda, I Médah, S Shendale, LN Lochlainn… - Vaccine, 2020 - Elsevier
Background Despite the remarkable achievements of the Expanded Programme on
Immunization (EPI) in Burkina Faso, numerous challenges remain, including missed …
Immunization (EPI) in Burkina Faso, numerous challenges remain, including missed …
[HTML][HTML] Meningococcal A conjugate vaccine coverage in the meningitis belt of Africa from 2010 to 2021: a modelling study
RG Bender, J Shen, A Aravkin, AAB Fouda… - …, 2023 - thelancet.com
Background As of the end of 2021, twenty-four countries in the African meningitis belt have
rolled out mass campaigns of MenAfriVac®, a meningococcal A conjugate vaccine (MACV) …
rolled out mass campaigns of MenAfriVac®, a meningococcal A conjugate vaccine (MACV) …
[HTML][HTML] Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional …
S Mbaeyi, E Sampo, K Dinanibè, I Yaméogo… - The Lancet Infectious …, 2020 - thelancet.com
Background In the first 2 years after a nationwide mass vaccination campaign of 1–29-year-
olds with a meningococcal serogroup A conjugate vaccine (MenAfriVac) in Burkina Faso …
olds with a meningococcal serogroup A conjugate vaccine (MenAfriVac) in Burkina Faso …
[HTML][HTML] Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule …
SF Nkwenkeu, MF Jalloh, JA Walldorf, RL Zoma… - BMC public health, 2020 - Springer
Background Meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017
into the routine childhood immunization schedule (at 15–18 months of age) in Burkina Faso …
into the routine childhood immunization schedule (at 15–18 months of age) in Burkina Faso …
[HTML][HTML] Recent setbacks in measles elimination: the importance of investing in innovations for immunizations
JL Goodson - The Pan African Medical Journal, 2020 - ncbi.nlm.nih.gov
The recent setbacks in efforts to achieve measles elimination goals are alarming. To reverse
the current trends, it is imperative that the global health community urgently intensify efforts …
the current trends, it is imperative that the global health community urgently intensify efforts …
[HTML][HTML] Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment …
BN Aksnes, JA Walldorf, SF Nkwenkeu, RL Zoma… - Vaccine, 2021 - Elsevier
Abstract Background In March 2017, Burkina Faso introduced meningococcal serogroup A
conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is …
conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is …
Implementation of the Meningitis Vaccine Project in Africa: lessons for vaccine implementation programs.
O Ezezika, M Mengistu, T Lear - Journal of Global Health Reports, 2021 - ir.lib.uwo.ca
Background The Meningitis Vaccine Project (MVP) was an international partnership that
began in 2010 and focused on the development, testing, licensure, and widespread …
began in 2010 and focused on the development, testing, licensure, and widespread …